Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT06696716

ONO-4059 Study in Patients With Steroid-resistant Pemphigus

Conditions: Pemphigus, Steroid-resistant Pemphigus

Sex: All

Ages: 20 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 34

Sponsor: Ono Pharmaceutical Co., Ltd.

Location: Ichinomiya Municipal Hospital Aichi

Summary

ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus

Eligibility Criteria

Inclusion Criteria: * Patients with a diagnosis of pemphigus * Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent Exclusion Criteria: * Patients with an active infection * Patients with malignancy * Patients with past history of serious allergy or anaphylaxis

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06696716). StuddyBuddy aggregates publicly available trial information.